These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 15742096)

  • 1. [Conjugated and polysaccharide anti-pneumococcal vaccines].
    Valdez R; Sukster E
    J Pediatr (Rio J); 2005; 81(1):88. PubMed ID: 15742096
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of pneumococcal polysaccharide vaccine on nonbacteremic pneumococcal pneumonia.
    Weiser JN; Austrian R
    Clin Infect Dis; 2007 Apr; 44(8):1139-40; author reply 1140-1. PubMed ID: 17366469
    [No Abstract]   [Full Text] [Related]  

  • 3. Comparing potential benefits of new pneumococcal vaccines with the current polysaccharide vaccine in the elderly.
    Fry AM; Zell ER; Schuchat A; Butler JC; Whitney CG
    Vaccine; 2002 Dec; 21(3-4):303-11. PubMed ID: 12450706
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How many is enough? Will conjugated pneumococcal vaccines with more serotypes and fewer doses work better?
    Lu CY; Huang LM
    J Formos Med Assoc; 2011 Feb; 110(2):67-9. PubMed ID: 21377059
    [No Abstract]   [Full Text] [Related]  

  • 5. Pneumococcal conjugate vaccine.
    Ledwith M
    Curr Opin Pediatr; 2001 Feb; 13(1):70-4. PubMed ID: 11176248
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Experience with pneumococcal polysaccharide conjugate vaccine (conjugated to CRM197 carrier protein) in children and adults.
    Durando P; Faust SN; Fletcher M; Krizova P; Torres A; Welte T
    Clin Microbiol Infect; 2013 Oct; 19 Suppl 1():1-9. PubMed ID: 24083785
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hyporesponsiveness and its clinical implications after vaccination with polysaccharide or glycoconjugate vaccines.
    Poolman J; Borrow R
    Expert Rev Vaccines; 2011 Mar; 10(3):307-22. PubMed ID: 21434799
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increasing focus on local epidemiology demonstrates potential value of pneumococcal conjugate vaccines in Middle East and North Africa Region.
    Pelton SI
    Vaccine; 2012 Dec; 30 Suppl 6():G1. PubMed ID: 23228351
    [No Abstract]   [Full Text] [Related]  

  • 9. Tolerability and immunogenicity of an eleven valent mixed carrier Streptococcus pneumoniae capsular polysaccharide-diphtheria toxoid or tetanus protein conjugate vaccine in Finnish and Israeli infants.
    Dagan R; Kayhty H; Wuorimaa T; Yaich M; Bailleux F; Zamir O; Eskola J
    Pediatr Infect Dis J; 2004 Feb; 23(2):91-8. PubMed ID: 14872172
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pneumococcal conjugate vaccine--relevance for developing countries.
    Mulholland K
    Indian Pediatr; 2001 May; 38(5):453-60. PubMed ID: 11359971
    [No Abstract]   [Full Text] [Related]  

  • 11. Use of the new pneumococcal conjugate vaccine in the USA.
    Baucher H
    Arch Dis Child; 2000 Nov; 83(5):396. PubMed ID: 11040145
    [No Abstract]   [Full Text] [Related]  

  • 12. An update on the new pneumococcal conjugate vaccine.
    Holland MJ
    Pediatr Ann; 2001 Sep; 30(9):515-6. PubMed ID: 11554259
    [No Abstract]   [Full Text] [Related]  

  • 13. Vaccine Update: Recommendation for conjugate pneumococcal and pneumococcal polysaccharide vaccines in adults older than 65 years.
    Niemi SA; Foster SL; Hayney MS
    J Am Pharm Assoc (2003); 2015; 55(2):212, 214-5. PubMed ID: 25749266
    [No Abstract]   [Full Text] [Related]  

  • 14. Phase 3 trial evaluating the immunogenicity, safety, and tolerability of manufacturing scale 13-valent pneumococcal conjugate vaccine.
    Gadzinowski J; Albrecht P; Hasiec B; Konior R; Dziduch J; Witor A; Mellelieu T; Tansey SP; Jones T; Sarkozy D; Emini EA; Gruber WC; Scott DA
    Vaccine; 2011 Apr; 29(16):2947-55. PubMed ID: 21335032
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Capsules, clones, and curious events: pneumococcus under fire from polysaccharide conjugate vaccine.
    Long SS
    Clin Infect Dis; 2005 Jul; 41(1):30-4. PubMed ID: 15937759
    [No Abstract]   [Full Text] [Related]  

  • 16. Immunogenicity of a 23-valent pneumococcal polysaccharide vaccine among Mexican children.
    Espinosa-Padilla SE; Murata C; Estrada-Parra S; Santos-Argumedo L; Mascareñas C; Franco-Paredes C; Espinosa-Rosales FJ
    Arch Med Res; 2012 Jul; 43(5):402-5. PubMed ID: 22868187
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Pneumococcal vaccines in adults: an update].
    Blamey R
    Rev Chilena Infectol; 2014 Oct; 31(5):607-9. PubMed ID: 25491461
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modelling the costs and effects of a universal infant immunization program using conjugated pneumococcal vaccine in British Columbia.
    Moore D; Bigham M; Patrick D
    Can Commun Dis Rep; 2003 Jun; 29(11):97-104. PubMed ID: 12794969
    [No Abstract]   [Full Text] [Related]  

  • 19. Prevention of pneumococcal disease in children. Pneumococcal conjugate vaccines: their use globally could have a major impact on public health.
    Kyaw MH; Jones IG; Campbell H
    Acta Paediatr; 2001 May; 90(5):473-6. PubMed ID: 11430703
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Two pneumococcal vaccines: the 7-valent conjugate vaccine (Prevenar) for children up to the age of 5 years and the 23-valent polysaccharide vaccine (Pneumo 23) for the elderly and specific groups at risk].
    de Greeff SC; Sanders EA; de Melker HE; van der Ende A; Vermeer PE; Schouls LM
    Ned Tijdschr Geneeskd; 2007 Jun; 151(26):1454-7. PubMed ID: 17633974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.